Biology and management of malignant pleural mesothelioma
- 1 November 2006
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 42 (16), 2706-2714
- https://doi.org/10.1016/j.ejca.2006.07.011
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trialAnnals of Oncology, 2005
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- The pathogenesis of mesotheliomaSeminars in Oncology, 2002
- Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesotheliomaOncogene, 2000
- Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesotheliomaJournal of Cellular Physiology, 1999
- The European mesothelioma epidemicBritish Journal of Cancer, 1999
- Asbestos induces inflammatory cytokines in the lung through redox sensitive transcription factorsToxicology Letters, 1998
- Asbestos induction of nuclear transcription factors and interleukin 8 gene regulation.American Journal of Respiratory Cell and Molecular Biology, 1996
- Asbestos induces nuclear factor kappa B (NF-kappa B) DNA-binding activity and NF-kappa B-dependent gene expression in tracheal epithelial cells.Proceedings of the National Academy of Sciences of the United States of America, 1995
- Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: Possible sites of tumor suppressor genesGenes, Chromosomes and Cancer, 1989